Skip to main content
logo
Mirion Technologies, Inc. (MIR)
NYSE: MIR · Real-Time Price · USD
17.08
-1.14 (-6.26%)
At close: Jun 5, 2026, 4:00 PM EDT
17.10
+0.02 (0.12%)
After-hours: Jun 5, 2026, 7:46 PM EDT

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Cancer Care Revenue
243.40M237.00M228.10M
Cancer Care Revenue Growth
2.70%3.90%5.65%
Other Medical Revenue
70.90M73.80M71.60M
Other Medical Revenue Growth
-3.93%3.07%4.37%
Total Medical Revenue
314.30M310.80M299.70M
Total Medical Revenue Growth
1.13%3.70%5.34%
Nuclear Revenue
416.20M374.60M316.60M
Nuclear Revenue Growth
11.11%18.32%8.50%
Labs and Research Revenue
123.70M122.20M131.70M
Labs and Research Revenue Growth
1.23%-7.21%7.16%
Other Nuclear & Safety Revenue
126.80M117.80M112.80M
Other Nuclear & Safety Revenue Growth
7.64%4.43%10.91%
Total Nuclear & Safety Revenue
666.70M614.60M561.10M
Total Nuclear & Safety Revenue Growth
8.48%9.54%8.66%
Revenue (Total)
981.00M925.40M860.80M
Revenue (Total) Growth
6.01%7.51%7.48%

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
North America Revenue
626.40M582.20M542.20M
North America Revenue Growth
7.59%7.38%5.84%
Europe Revenue
340.10M327.60M305.60M
Europe Revenue Growth
3.82%7.20%12.31%
Asia Pacific Revenue
14.50M15.60M13.00M
Asia Pacific Revenue Growth
-7.05%20.00%-21.21%
Revenue (Total)
981.00M925.40M860.80M
Revenue (Total) Growth
6.01%7.51%7.48%

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Product Revenue
739.70M690.60M643.10M
Product Revenue Growth
7.11%7.39%7.58%
Service Revenue
241.30M234.80M217.70M
Service Revenue Growth
2.77%7.85%7.19%
Revenue (Total)
981.00M925.40M860.80M
Revenue (Total) Growth
6.01%7.51%7.48%

Adjusted EBITDA

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Adjusted EBITDA
117.80M116.40M104.60M
Medical Adjusted EBITDA Growth
1.20%11.28%7.28%
Nuclear & Safety Adjusted EBITDA
185.30M177.70M159.80M
Nuclear & Safety Adjusted EBITDA Growth
4.28%11.20%18.02%
Corporate & Other Adjusted EBITDA
-67.60M-66.20M-60.80M
Operating Income (Total)
46.50M51.50M24.80M
Operating Income (Total) Growth
-9.71%107.66%-

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Income from Operations
48.00M46.90M22.30M
Medical Income from Operations Growth
2.34%110.31%71.54%
Nuclear & Safety Income from Operations
100.30M101.10M78.90M
Nuclear & Safety Income from Operations Growth
-0.79%28.14%71.52%
Corporate & Other Income from Operations
-101.80M-96.50M-76.40M
Operating Income (Total)
46.50M51.50M24.80M
Operating Income (Total) Growth
-9.71%107.66%-

Capital Expenditures

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Medical Capital Expenditures
19.20M20.20M27.80M
Medical Capital Expenditures Growth
-4.95%-27.34%27.52%
Nuclear & Safety Capital Expenditures
20.00M18.70M17.70M
Nuclear & Safety Capital Expenditures Growth
6.95%5.65%-1.67%
Corporate & Other Capital Expenditures
1.00M700.00K3.30M
Corporate & Other Capital Expenditures Growth
42.86%-78.79%230.00%

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2021FY 2020FY 2020FY 2019
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Jun '21 Dec '20 Jun '20 Jun '19
Remaining Performance Obligations (RPO)
1.12B1.10B811.90M
Remaining Performance Obligations (RPO) Growth
1.48%36.01%-5.27%
Remaining Performance Obligations (RPO) to be Recognized Over NTM
36.00%49.00%54.00%
Order Book
1.12B1.03B843.00M
Order Book Growth
8.43%22.42%-7.26%
Medical - Organic Revenue Growth
-3.10%2.60%
Nuclear & Safety - Organic Revenue Growth
-4.40%8.80%
Total Organic Revenue Growth
-3.90%6.60%
Updated Apr 29, 2026. Data Source: Fiscal.ai.